Vivacta Biotechnology, a Shanghai‑based pioneer of in‑vivo CAR‑T platforms, closed a combined Series A and Series A+ round that raised more than US$50 million. The financing, led by Loyal Valley Capital and Decheng Capital and backed by heavyweight biotech investors such as OrbiMed, Eisai Innovation and Qiming Venture Partners, underscores the growing appetite among sovereign wealth funds and regional venture houses for next‑generation cell‑therapy assets. For MENA capital allocators, the deal validates a strategic shift toward late‑stage immuno‑oncology pipelines that can be commercialised across both emerging and mature markets, offering a lucrative diversification vector beyond traditional oil‑linked portfolios.
The proceeds will fund the accelerated clinical development of Vivacta’s lead candidate, GT801, which has already demonstrated a favourable safety and efficacy signal in early‑phase trials for hematologic malignancies and autoimmune disorders. By expanding the research team, advancing regulatory dossiers and scaling manufacturing capability, Vivacta aims to position GT801 for rapid market entry in the United States, Europe and Asia. The presence of OrbiMed – a global health‑care fund with a $20 billion AUM footprint – and the appointment of Loyal Valley’s Xie Ronggang to the board, further embeds the company in an international capital network that MENA investors can tap for co‑investment and downstream distribution partnerships.
From a regional infrastructure perspective, the financing highlights a converging ecosystem where Chinese biotech expertise and Middle‑East financing can jointly address the scarcity of advanced cell‑therapy production facilities in the GCC and North Africa. Sovereign wealth entities such as the Abu Dhabi Investment Authority and Saudi Arabia’s Public Investment Fund are increasingly allocating capital to cross‑border biotech ventures, seeking to leverage the scalability of in‑vivo CAR‑T technologies that require less ex‑vivo manufacturing complexity. Vivacta’s roadmap—encompassing clinical trial sites, regulatory engagement and a global commercial launch—offers a template for future MENA‑led joint ventures that could anchor a regional hub for cell‑therapy R&D, contract manufacturing and patient access.
In sum, the US$50 million round not only furnishes Vivacta with the financial runway to bring GT801 to market but also creates a conduit for MENA sovereign and venture capital to integrate into the fast‑moving frontier of cellular immunotherapy. The transaction signals a maturing investment thesis in the region: backing platforms that marry groundbreaking science with scalable commercial models will be pivotal for building a resilient, diversified health‑care portfolio that can deliver both strategic returns and vital therapeutic outcomes for Middle‑East and North‑African populations.
